In recurrent tumours, GR replaces AR to activate a set of similar yet distinguishable target genes, which is crucial for maintaining the resistant phenotype41, and this is also an important reason for the sustained high expression of TDO2 in recurrent tumours. This evidence concerns the gene NR3C1 and neoplasm.